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Recently,  there  have  been  remarkable  advances  in  regenerative  medicine,  and  almost  all  disorders  of  the
oral  and maxillofacial  region  could  be research  targets  of  regenerative  medicine.  Meanwhile,  treatment
in  this  region  has  been  well  established  using  biomaterials,  prostheses,  and  microsurgery.  Therefore,  to
surpass  such  a  conventional  approach  as  an  alternative,  regenerative  medicine  should  take  an  approach
of  being  less  invasive  and/or  more  effective.  In this  report,  we present  our  preclinical  and clinical research
on  bone  and cartilage  regenerative  medicine  in  the  oral  and maxillofacial  region.
Regarding  bone  regenerative  medicine,  we have  tried  to  develop  artiﬁcial  bone that  would  maximize
bone  formation  at the  transplanted  site,  but would  subsequently  be  replaced  by autologous  bone.  We
have  made  custom-made  artiﬁcial  bone  (CT-Bone)  using  alpha-tricalcium  phosphate  (-TCP)  particles
and  an  ink-jet  printer,  and  have  conducted  clinical  research  and  trials  on 30  patients.To  develop  tissue-engineered  cartilage  with  proper  three-dimensional  (3D)  morphological  form  and
mechanical  strength,  we  have  optimized  the  culture  medium  of chondrocytes  and  the  scaffold.  Fol-
lowing  a preclinical  study  conﬁrming  efﬁcacy  and  safety,  we  have  conducted  clinical  research  in three
patients  with  nasal  deformity  associated  with  cleft  lip  and  palate,  and  are now  starting  multicenter  clinical
research.
©  2014  Japanese  Stomatological  Society.  Published  by Elsevier  Ltd.  All  rights  reserved.ontents
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Fig. 1. Bone reconstruction using particulate cancellous bone and marrow (PCBM)
in combination with a titanium mesh tray (excerpted from Ref. [3] with permission).
(A)  A case of reconstruction using PCBM and a titanium mesh tray. Nine-month post-
operative panoramic view showing the successfully reconstructed mandible. The
occlusal function of this patient is quite good with her remaining natural dentition6 T. Takato et al. / Oral Scienc
. Introduction
The concept of tissue engineering, that is, seeding cells on a
caffold and inducing tissue formation in the presence of growth
actors, was proposed by Professor Joseph Vacanti of Harvard
niversity and Professor Robert Langer of the Massachusetts
nstitute of Technology in 1993 [2]. The photograph of a human
ar mounted on the back of a mouse they presented was cov-
red widely by the mass media throughout the world, gaining
mmediate fame for regenerative medicine. Thereafter, research in
he ﬁeld of regenerative medicine has advanced greatly. Two years
go, Professor Shinya Yamanaka of Kyoto University was awarded
he Nobel Prize, and induced pluripotent stem cells (iPS) cells and
egenerative medicine have also become hot topics in Japan.
In  the maxillofacial region, nearly all disorders have become
esearch subjects of regenerative medicine, including loss of teeth
nd periodontal tissue due to caries and periodontal disease,
ypoplasia or defects of bone and cartilage associated with con-
enital anomalies, such as cleft lip and palate, defects of bone,
artilage, and soft tissues due to tumors or trauma, and xerostomia.
owever, the dental ﬁeld has a long history of knowledge of mate-
ials, and treatment using biological materials has been established
uch as crown prostheses, dentures, dental implants, and epitheses.
n addition, with the recent advancements in medical technology,
econstruction of large mandibular defects has become possible
y microsurgical operations. Therefore, to surpass such a conven-
ional approach as an alternative, regenerative medicine should
ake an approach of being less invasive and/or more effective. Par-
icularly, the application of regenerative medicine is considered to
e advantageous for the maxillofacial region because the weight
oad is smaller than in the limb, and the amount of tissue needed
or reconstruction is generally small. In this report, we  present our
reclinical and clinical research on bone and cartilage regenerative
edicine in the oral and maxillofacial region.
. In situ tissue engineering in maxillofacial region
After tumor resection or trauma in the maxillofacial region,
one defects occasionally impair the function of mastication and
he facial appearance of patients, worsening their quality of life
QOL). To reconstruct such defects, many surgical procedures have
een developed including block bone graft and vascularized bone
raft. Especially in mandibular reconstruction, a vascularized free
raft of the ﬁbula is preferably chosen because: (1) a sufﬁciently
ong bone with vessels can be harvested, (2) it is thick enough for
lacing dental implants, (3) the bone graft can be harvested during
anipulation in the head region, (4) skin grafting can be addition-
lly performed, and (5) complications of the donor site are rare.
owever, this operation requires intraoperative trimming of the
one graft to adjust its shape to the recipient site, making it dif-
cult to provide satisfactory morphological form. In addition, it is
ighly invasive at the donor site, and there are limitations in the
ize and shape of the grafts.
For  these reasons, particulate cancellous bone and marrow
PCBM) from the ilium is often transplanted in combination with a
itanium mesh tray (Fig. 1) [3]. By appropriate shaping of the tray,
his method enables more morphologically natural reconstruction,
hile restoration of adequate occlusion is also possible with the
se of dentures and dental implants. Moreover, mesenchymal cells
n PCBM can induce new bone formation and subsequent bone
esorption, resulting in bone remodeling that matches the sur-
ounding recipient bone. This is a peculiar property of PCBM, in
ontrast to the aim of a conventional block bone or vascularized
one graft, which is the survival of the graft bones itself. Due to
his osteogenic ability of PCBM, reconstruction using PCBM can beand  removable partial denture. (B) Intraoperative view after PCBM grafting. PCBM
was loaded into the mesh and densely condensed as much as possible.
regarded as in situ tissue engineering (it can also be considered
“in vivo tissue engineering,” because tissue regeneration proceeds
after transplantation) [4]. Another example based on in situ tis-
sue engineering in the maxillofacial region is bone lengthening for
micrognathia, in which bone formation can be induced by mild trac-
tion on the callus of an osteotomy site. It is therefore considered that
regenerative medicine may  not be such a new approach, as some
conventional treatments adopt the concepts of tissue engineering.
3. Preclinical research on bone regenerative medicine
Vascularized bone and block bone are considered to retain the
intrinsic properties of bone, because they contain the original cell
components and growth factors accumulated in the matrix. There-
fore, bone union after grafting of these bones usually progresses
smoothly, resulting in a favorable clinical outcome. Transplantation
of PCBM with a titanium mesh tray also exhibits excellent results.
However, as long as autologous transplantation is used, these oper-
ations include the process of harvesting tissues, and the amount
obtained for grafts may  be limited.
In foreign countries, particularly in the United States, use of allo-
geneic bone is prevalent. The amount and shape of bone grafts can
be managed with allogeneic grafting, and the operation is less inva-
sive with respect to the donor site. While cells in allogeneic bone
are not viable and the activity of growth factors in the matrix is sup-
pressed by freezing, the grafts are still natural bone with excellent
function. However, the use of allogeneic bone has not been preva-
lent in Japan because of concerns of infection and ethical issues.
Instead, calcium phosphate-based artiﬁcial bone has been used as
an alternative [5]. The reason why calcium phosphate is preferred is
that being a component of bone, it has an excellent biocompatibility
and biological safety. Besides, the supply of calcium phosphate is
unlimited as it is synthesized from limestone and phosphate rock.
T. Takato et al. / Oral Science International 11 (2014) 45–51 47
F  was s
D  phosp
I
m
a
d
d
a
t
i
v
h
t
u
a
(
o
w
i
C
p
d
t
b
4
t
r
n
F
u
o
aig. 2. Fabrication of custom-made artiﬁcial bone (CT-Bone). The design of CT-Bone
ICOM  data by CT imaging. Then, CT-Bone was printed using laminating tricalcium
n the application of artiﬁcial bone, calcium phosphate is usually
anufactured into porous blocks, granules, or paste. As granules
nd paste cannot retain a given shape, they are mostly used to ﬁll
efects. Porous blocks can retain their shape, but require trimming
uring operation, failing in manipulability and precision. Overall,
rtiﬁcial bone remains inferior to autogenous or allogeneic bone in
erms of strength, morphological form, manipulability, degradabil-
ty, resorbability, and osteogenic ability.
To that end, we, together with Professor Ung-il Chung of the Uni-
ersity of Tokyo and Graduate Schools of Engineering and Medicine,
ave developed artiﬁcial bone that would maximize bone forma-
ion, but would be subsequently replaced by autologous bone. We
sed computed tomography (CT) image to make custom-made
rtiﬁcial bone (CT-Bone) that would ﬁt the defect of each patient
Fig. 2). Regarding the procedure, we designed the shape of CT-Bone
n a three-dimensional (3D) plaster ﬁgure of the patient using wax,
hich was then converted to Digital Imaging and Communications
n Medicine (DICOM) data after CT imaging. Based on the data,
T-Bone was fabricated with a 3D ink-jet printer [6]. During 3D
rinting, a thin layer (0.1 mm)  of tricalcium phosphate (TCP) pow-
er was ﬁrst made, and then a hardening liquid was sprayed over
he powder. By repeating the process, not only the external shape
ut also the internal structure of artiﬁcial bone can be fabricated.
.  Clinical application of custom-made artiﬁcial boneAfter  performing preclinical studies using large experimen-
al animals, from March to July 2006 we conducted clinical
esearch on CT-Bone in 10 patients with maxillofacial deformities in
on-weight-bearing regions because of congenital malformation,
ig. 3. Clinical application of CT-Bone: Case 1 (excerpted from Ref. [7] with permission).
sing wax  (Middle), which was then converted to DICOM data after CT imaging. CT-Bo
peration. (C) Preoperative and postoperative photographs of patient’s face. (D) CT image
t  the recipient site has been conﬁrmed.haped on a 3D plaster ﬁgure of the patient with wax, which was then converted to
hate powder with a 3D ink-jet printer.
trauma,  or tumor resection. Subsequently, a clinical trial was  con-
ducted in another 20 patients from October 2008 to September
2009 (Figs. 3 and 4) [7,8]. As CT-Bone was prepared from the
patients’ CT images, it ﬁtted the recipient sites well, and did not
require adjustment of the shape during operations. In addition,
the grafts were strong enough to tolerate the impact of the opera-
tion (20 MPa) without sintering after modeling, showing excellent
manipulability. Thus far, the outcomes have been non-problematic
in terms of safety, and union between CT-Bone and self-bone at
the recipient site has been conﬁrmed. However, we need to bear in
mind that CT-Bone is still a foreign material at the time of transplan-
tation, and thus should not be transplanted at irradiated or infected
sites.
To broaden the application of CT-Bone to weight-bearing
regions, we are now developing highly functional artiﬁcial bone
by hybridization with other materials including metals and fusion
with bone-inducing signals. As CT-Bone does not have sufﬁ-
cient mechanical properties for the reconstruction of segmentally
resected mandible, we  are now developing another approach for
bone regeneration in such cases.
5. Research background of cartilage regenerative medicine
Cartilage  is present in not only joints and intervertebral discs
but also the nose, ear, and trachea in the head and neck region.
It plays an important role in maintaining morphological form and
activities of daily life. Cartilage is generally deﬁcient in self-repair
ability, and once it is damaged, spontaneous restoration is unlikely
to occur. Therefore, trauma such as injury of articular cartilage,
age-associated disorders such as osteoarthritis, and inﬂammatory
 (A) On a 3D plaster model of the patient (Left), the design of CT-Bone was  shaped
ne was  fabricated by an ink-jet printer (Right). (B) Transplanted CT-Bone during
s just after and 2-years after the operation. Union between CT-Bone and self-bone
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ostoperative CT images.
isorders such as rheumatoid arthritis often impair the activities
f patients. Conventional treatment by joint replacement or autol-
gous cartilage grafting has problems, such as poor durability,
nfection, and invasiveness to the donor site.
In the ﬁeld of regenerative medicine, cartilage regenerative
edicine is relatively advanced, along with regeneration of skin
nd cornea. Autologous chondrocyte implantation (ACI) has been
idely introduced, particularly in Europe and the United States
9]. In the original method of ACI for local defects in articular
artilage, chondrocytes, isolated from articular cartilage of non-
eight-bearing regions, are proliferated by culture, administered
nto the defects as a cell suspension, and the donor site is cov-
red with a periosteal patch to prevent leakage (Fig. 5). However,
he indications for ACI are still limited, and complications such as
aminar detachment, thickening of the periosteal patch, and graft
isplacement have been reported [10]. In addition, it has been sug-
ested that there may  not be a clear clinical advantage compared
ig. 5. Autologous chondrocyte implantation (ACI). Various types of ACI have been
eveloped, including the original one (A), one with substitution of the periosteal
atch  with collagen membrane (B), and all-in-one type using animal-derived bio-
aterials (C). (A) CT image of plaster model with the structure of CT-Bone. (B) Structural design
g. (D) Preoperative and postoperative photographs of patient’s face. (E) One-year
with conventional treatment [11]. In Japan, the group of Professor
Mitsuo Ochi of Hiroshima University developed a method of trans-
plantation of chondrocytes embedded in collagen gel [12]. This
technique was  transferred to Japan Tissue Engineering Co., Ltd., and
has been covered by health insurance from April 1, 2013 as autoge-
nous cultured cartilage “JACC®.” Regarding cartilage regenerative
medicine in the maxillofacial region, subcutaneous cartilage regen-
eration has been used to treat patients in whom a silicone implant
has been removed after augmentation rhinoplasty and those with
saddle nose [13]. In these treatments, chondrocytes isolated from
the patients’ cartilage were expanded and injected into a subcuta-
neous pocket.
However, the present protocols for cartilage regenerative
medicine either in the knee or in the nose utilize cells in solution
or gel form, and thus are not sufﬁcient for reconstruction requiring
3D morphological form.
6.  Preclinical research on cartilage regenerative medicine
To  develop tissue-engineered cartilage with 3D form and rigid-
ity for the treatment of patients with severe nasal deformity
associated with cleft lip and palate, we have conducted our research
from the perspective of three elements of tissue engineering, that
is, cells, growth factors, and scaffolds.
The choice of cells for cartilage regeneration varies from chon-
drocytes derived from cartilage tissue, to various cells classiﬁed as
tissue stem cells, to embryonic stem cells (ES cells) and induced
pluripotent stem cells (iPS cells). Of these, we considered that the
use of autologous auricular chondrocytes would be practical and
advantageous for early clinical application, because they: (1) pro-
liferate vigorously in cell culture [14], (2) mature spontaneously
after transplantation, (3) have a low risk of immune rejection or
malignant transformation, (4) are relatively easy to harvest, and
(5) pose no ethical problems.
We then examined factors that could efﬁciently induce the
proliferation of human auricular chondrocytes. Of 12 growth
factors/hormones conﬁrmed to be safe as drugs (FGF-2, IGF-
I, insulin, BMP-2, etc.), basic ﬁbroblast growth factor (FGF-2;
100 ng/mL) showed the highest proliferation efﬁciency when
added to 5% human serum as a single factor. Proliferation of
chondrocytes could be further enhanced by combining insulin
T. Takato et al. / Oral Science International 11 (2014) 45–51 49
Fig. 6. Evaluation of scaffolds (porous material) for implant-type tissue-engineered cartilage (excerpted from Ref. [17] with permission). Macroscopic and histological
images of tissue-engineered constructs made of porous scaffolds consisting of various biodegradable polymers with a chondrocytes/atelocollagen mixture with cell density
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tilage has been approved by the Institutional Review Board as well
as the Ministry of Health, Labour and Welfare of Japan (MHLW).
We have conducted clinical research on the patients with nasal
deformity associated with cleft lip and palate at the Department off  1 × 10 cells/mL. The constructs (4 mm × 4 mm × 3 mm)  were transplanted into 
olymers. Based on the toluidine blue histological ﬁndings, metachromatic areas
acroscopic images (bar = 2 mm);  histology, bar = 1 mm (lower magniﬁcation) and 
5 g/mL) with FGF-2 (100 ng/mL) and 5% human serum, realizing
000-fold proliferation of human chondrocytes in 3 weeks [15].
Regarding  scaffolds for tissue-engineered cartilage, we aimed to
evelop a composite scaffold consisting of hydrogel and a porous
aterial that retains the advantages of both components. With
espect to hydrogel, we have chosen atelocollagen gel, because it
as a high cell-retaining capacity, promotes the expression and
roduction of cartilage matrix, and is already being used clinically
16]. Meanwhile, to select a porous material, we compared sev-
ral biodegradable polymers including poly-l-lactic acid (PLLA),
oly-glycol acid (PGA), and poly-lactic acid/glycol acid (PLGA),
hich have been used clinically for plates, screws, and resorbable
utures. When evaluated in detail regarding pore size, porosity, and
anufacturing method, PLLA and PLGA scaffold prepared by the
ugar-leaching method with a pore size of 0.3 mm and porosity of
5% showed satisfactory mechanical strength. We  then conducted
nimal experiments, in which human auricular chondrocytes in
hese scaffolds were transplanted subcutaneously in athymic
ude mice. Histological and biochemical analysis demonstrated
hat the constructs using PLGA scaffold showed better cartilage
egeneration (Fig. 6) [17]. However, in beagles, when auricular
hondrocytes from 8-month-old male beagles were applied to
LGA scaffolds and transplanted subcutaneously into the back
f the same animals, dense accumulation of macrophages was
bserved in tissue-engineered cartilage, and the tissue shrank after
 months. In the case of using PLLA scaffolds, cartilage regeneration
as found in the constructs 1 month after transplantation, and
ature cartilage was observed after 6 months [18]. The reason why
LGA scaffold-based tissue-engineered cartilage, which showed
atisfactory results in nude mice, failed in beagles may  be related
o the difference in tissue reaction against the two scaffolds.
ompared to PLLA, degradation of PLGA is known to proceed
ather rapidly after transplantation, releasing proinﬂammatory
ubstances into tissues. Because beagles have a normal immune
ystem, these substances may  provoke excessive tissue reaction,
nhibiting cartilage regeneration. On the basis of these evaluations,
e have selected porous PLLA scaffold (pore size: 0.3 mm,  porosity:cks of nude mice. At 2 months in vivo, the skin surface was smooth with all the
 more expansive than those in the experiment using 1 × 107 cells/mL. Macro and
m (higher magniﬁcation).
95%)  for tissue-engineered cartilage that can be implanted for the
treatment of patients with severe nasal deformity associated with
cleft lip and palate (implant-type tissue-engineered cartilage).
7.  Clinical application of implant-type tissue-engineered
cartilage
Implant-type tissue-engineered cartilage consists of autologous
chondrocytes that have been cultured in a medium containing
5% autologous serum and FGF2/insulin, atelocollagen gel (Koken,
Tokyo, Japan), which has been approved as a medical device and
as a PLLA porous scaffold (Fig. 7). PLLA porous scaffold has a domal
structure with a length of 5 cm,  width of 6 mm,  and height of 3 mm,
and has been used to treat nasal deformity associated with cleft
lip and palate. Following a preclinical study conﬁrming efﬁcacy
and safety, our protocol for implant-type tissue-engineered car-Fig. 7. Structure of implant-type tissue-engineered cartilage. It contains autologous
chondrocytes,  atelocollagen gel and a PLLA porous scaffold. The scaffold has a domal
structure with length 5 cm, width 6 mm,  and height 3 mm.
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cig. 8. Protocol of our clinical research on implant-type tissue-engineered cartilage.
re cultured and expanded with a medium containing autoserum and FGF-2/insul
ransplanted into the patient’s nose.
ral and Maxillofacial Surgery, University of Tokyo Hospital (Fig. 8).
irst, we obtained biopsy of auricular cartilage of around 0.1 g
rom the patients. The isolated chondrocytes were cultured with
utoserum and FGF-2/insulin for a month. The cultured cells were
hen administered into the PLLA scaffold, and then the construct
as transplanted into the patient’s nose.
More than 2.5 years have passed since the ﬁrst transplantation
f tissue-engineered cartilage. Thus far, no serious adverse event
equiring graft removal has been observed, and the clinical outcome
as been satisfactory in all patients. We  are now starting multicen-
er clinical research in cooperation with Tokyo Medical and Dental
niversity and Yamagata University to assess evaluation methods
or cartilage maturation, establish a transport system for tissue-
ngineered cartilage, and simplify the manufacturing process and
uality control.
.  Development of implant-type regenerated cartilage
Implant-type tissue-engineered cartilage has mechanical prop-
rties as cartilage tissue and the desired morphological form can
e achieved by adjustment of the shape of the scaffold. As it has
een conﬁrmed to be stable after transplantation in our clinical
esearch, we are now planning to widen its indications to other
issues including the trachea and joints.
Regarding tissue-engineered trachea, we are considering its
se for patients with tracheal stenosis. Autologous auricular
hondrocytes are applied to a PLLA scaffold for cartilage
egeneration, while micro-fabrication of the interior surface of a
LLA scaffold is expected to induce mucosal regeneration from
urrounding tissues. We  are evaluating the safety and efﬁcacy of
ur tissue-engineered trachea in rabbits and beagles, and will per-
orm an investigator-initiated clinical trial in six patients requiring
racheal reconstruction next year.
Regarding joints, we are developing a tissue-engineered joint
ith proper structure and sufﬁcient strength that can be applied in
atients with osteoarthritis. The construct is named NeoJoint; the
artilage part is prepared by administering cells in hydrogel into a
LLA scaffold, while the subchondral bone part is made of TCP artiﬁ-
ial bone. At present, we are conducting autologous transplantationlar cartilage around 0.1 g is taken from patients, and then the isolated chondrocytes
 a month. The cells are then administered into PLLA scaffold, and the construct is
in  Clawn miniature pigs using mesenchymal stem cells (MSCs) and
iPS cells as the cell source. With either cell type, cartilage regenera-
tion and bone repair have been observed on gross observation and
histological analysis.
Our  group has been engaged in the treatment of children with
cleft palate and microtia for many years. In the reconstruction of
microtia, the surgeon shapes ribs from the patient into an ear by
the surgeons. Unfortunately, however, this operation is esthetically
difﬁcult, as well as invasive at the donor site, and thus we consider
that the introduction of regenerative medicine would be beneﬁcial.
We hope that auricular reconstruction with a minimally invasive
and esthetically satisfying technique using iPS cells and a scaffold
prepared by 3D modeling will become possible.
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